Pub Date : 2023-01-01DOI: 10.4103/ds.ds-d-23-00064
Seungho Lee, W. Choi, Huiyoung Shin, Yujeong Park, J. Hong, AiYoung Lee
{"title":"Numerous osteoma cutis on the scalp caused by GNAS mutation","authors":"Seungho Lee, W. Choi, Huiyoung Shin, Yujeong Park, J. Hong, AiYoung Lee","doi":"10.4103/ds.ds-d-23-00064","DOIUrl":"https://doi.org/10.4103/ds.ds-d-23-00064","url":null,"abstract":"","PeriodicalId":11107,"journal":{"name":"Dermatologica Sinica","volume":"149 1","pages":""},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75848778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.4103/ds.ds-d-22-00201
S. Pradhan, Jinghong Huang, X. Ran, Chaoliang Zhang, D. Tsuruta, H. Imanishi, Y. Ran
{"title":"Combination simple wet gauze technique placating children and calcofluor white staining microscopy enhances the diagnostic capability in kerion","authors":"S. Pradhan, Jinghong Huang, X. Ran, Chaoliang Zhang, D. Tsuruta, H. Imanishi, Y. Ran","doi":"10.4103/ds.ds-d-22-00201","DOIUrl":"https://doi.org/10.4103/ds.ds-d-22-00201","url":null,"abstract":"","PeriodicalId":11107,"journal":{"name":"Dermatologica Sinica","volume":"40 1","pages":"62 - 63"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84885184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.4103/ds.ds-d-22-00154
S. Shao, Liang-Tseng Kuo, Yen-Ta Huang, P. Lai, Ching-Chi Chi
The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework offers a structured approach to assess the certainty of evidence (CoE) in systematic reviews (SRs). The CoE for each outcome falls into one of the four categories: very low, low, moderate, or high. The judgment of CoE is based on five downgrading factors (including the risk of bias, indirectness, inconsistency, imprecision, and publication bias) and three upgrading factors (including large effect size, dose-response relationship, and opposing plausible residual bias and confounding). To improve the transparency of SRs, authors should indicate how they grade the CoE for each outcome and provide a rationale for downgrading or upgrading the CoE.
{"title":"Using Grading of Recommendations Assessment, Development, and Evaluation (GRADE) to rate the certainty of evidence of study outcomes from systematic reviews: A quick tutorial","authors":"S. Shao, Liang-Tseng Kuo, Yen-Ta Huang, P. Lai, Ching-Chi Chi","doi":"10.4103/ds.ds-d-22-00154","DOIUrl":"https://doi.org/10.4103/ds.ds-d-22-00154","url":null,"abstract":"The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework offers a structured approach to assess the certainty of evidence (CoE) in systematic reviews (SRs). The CoE for each outcome falls into one of the four categories: very low, low, moderate, or high. The judgment of CoE is based on five downgrading factors (including the risk of bias, indirectness, inconsistency, imprecision, and publication bias) and three upgrading factors (including large effect size, dose-response relationship, and opposing plausible residual bias and confounding). To improve the transparency of SRs, authors should indicate how they grade the CoE for each outcome and provide a rationale for downgrading or upgrading the CoE.","PeriodicalId":11107,"journal":{"name":"Dermatologica Sinica","volume":"42 1","pages":"3 - 7"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75818825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.4103/ds.v41-3-editorial
Shang-Hung Lin
The prolonged use of masks has been reported to cause adverse skin reactions in both health-care workers (HCWs) and the public. In this issue of Dermatol Sinica, Ku et al. conducted a narrative review to identify different adverse skin reactions and associated risk factors in HCW and the public with prolonged use of masks during the COVID-19 pandemic.[1] They reported that retroauricular dermatitis, cheilitis, rosacea, acne vulgaris, nasal bridge damage, itch, allergic contact dermatitis, and irritant contact dermatitis are common mask-related adverse skin reactions. In addition, the long duration of wearing masks, preexisting skin diseases, and being HCWs are highlighted as definite risk factors. This review summarized the mask-related dermatoses and the associated risk factors. Therefore, it helps HCWs and the public adopt appropriate preventative measures based on their individualized circumstances. Vitiligo is a chronic autoimmune depigmenting skin disorder resulting from the selective destruction of melanocytes. The pathogenesis of vitiligo is complex and the therapeutic choice for vitiligo was limited in the past. The wood’s light, dermoscopy, and clinical photography were traditionally used to diagnose vitiligo. Interestingly, several potential biomarkers and advanced noninvasive skin imaging such as reflectance confocal microscopy and optical coherence tomography have recently assisted in evaluating vitiligo disease activity and severity. The clinical management of vitiligo is aimed at halting disease progression and facilitating repigmentation. In this issue of Dermatol Sinica, Shen et al. update the pathogenesis of vitiligo, discuss emerging biomarkers for the assessment of vitiligo disease activity and severity, and summarize prospective targeted therapies in treating vitiligo.[2] Various scientific and technological breakthroughs have been achieved in the field of medicine, especially in the field of dermatology, improving the accuracy of disease diagnosis and treatment to a new stage, in which the application of Artificial Intelligence (AI) has played an indispensable role. However, a study in 2020 found that while 85% of dermatologists were aware that AI is an emerging technology conducive to the development of dermatology, only 24% had a better understanding of the field.[3] In this issue of Dermatol Sinica, Ye and Chen review the recent new development of AI in dermatology, to promote dermatologists in the better understanding and mastering of it.[4] In this issue of Dermatol Sinica, Song et al. reported that hypertrophic scar patients owned elevated HOX transcript antisense intergenic RNA (HOTAIR) and decreased miR-30a-5p.[5] HOTAIR knockdown can inhibit the proliferation, migration, and collagen synthesis of scar fibroblasts by negatively regulating the expression of miR-30a-5p. Ye et al. reported that dupilumab showed good efficacy and safety in patients with photodermatoses through light-induced type 2 inflammatory response.[6
{"title":"How to prevent mask-related adverse skin reactions","authors":"Shang-Hung Lin","doi":"10.4103/ds.v41-3-editorial","DOIUrl":"https://doi.org/10.4103/ds.v41-3-editorial","url":null,"abstract":"The prolonged use of masks has been reported to cause adverse skin reactions in both health-care workers (HCWs) and the public. In this issue of Dermatol Sinica, Ku et al. conducted a narrative review to identify different adverse skin reactions and associated risk factors in HCW and the public with prolonged use of masks during the COVID-19 pandemic.[1] They reported that retroauricular dermatitis, cheilitis, rosacea, acne vulgaris, nasal bridge damage, itch, allergic contact dermatitis, and irritant contact dermatitis are common mask-related adverse skin reactions. In addition, the long duration of wearing masks, preexisting skin diseases, and being HCWs are highlighted as definite risk factors. This review summarized the mask-related dermatoses and the associated risk factors. Therefore, it helps HCWs and the public adopt appropriate preventative measures based on their individualized circumstances. Vitiligo is a chronic autoimmune depigmenting skin disorder resulting from the selective destruction of melanocytes. The pathogenesis of vitiligo is complex and the therapeutic choice for vitiligo was limited in the past. The wood’s light, dermoscopy, and clinical photography were traditionally used to diagnose vitiligo. Interestingly, several potential biomarkers and advanced noninvasive skin imaging such as reflectance confocal microscopy and optical coherence tomography have recently assisted in evaluating vitiligo disease activity and severity. The clinical management of vitiligo is aimed at halting disease progression and facilitating repigmentation. In this issue of Dermatol Sinica, Shen et al. update the pathogenesis of vitiligo, discuss emerging biomarkers for the assessment of vitiligo disease activity and severity, and summarize prospective targeted therapies in treating vitiligo.[2] Various scientific and technological breakthroughs have been achieved in the field of medicine, especially in the field of dermatology, improving the accuracy of disease diagnosis and treatment to a new stage, in which the application of Artificial Intelligence (AI) has played an indispensable role. However, a study in 2020 found that while 85% of dermatologists were aware that AI is an emerging technology conducive to the development of dermatology, only 24% had a better understanding of the field.[3] In this issue of Dermatol Sinica, Ye and Chen review the recent new development of AI in dermatology, to promote dermatologists in the better understanding and mastering of it.[4] In this issue of Dermatol Sinica, Song et al. reported that hypertrophic scar patients owned elevated HOX transcript antisense intergenic RNA (HOTAIR) and decreased miR-30a-5p.[5] HOTAIR knockdown can inhibit the proliferation, migration, and collagen synthesis of scar fibroblasts by negatively regulating the expression of miR-30a-5p. Ye et al. reported that dupilumab showed good efficacy and safety in patients with photodermatoses through light-induced type 2 inflammatory response.[6","PeriodicalId":11107,"journal":{"name":"Dermatologica Sinica","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135913337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.4103/ds.ds-d-23-00101
Yi-Hsien Chen, Jun Ma, Chien-Ping Chiang, Wei-Ming Wang, Chih-Tsung Hung
Dear Editor, A 64-year-old Taiwanese male, nonsmoker, with a history of hypertension and type 2 diabetes mellitus has been regularly taking metformin for glycemic control. The patient was previously diagnosed with biopsy-proven bullous pemphigoid after experiencing multiple itchy erythema and blisters all over the whole body for 3 months. He was treated with prednisolone 10 mg three times daily and azathioprine 25 mg daily. Lesions showed improvement during the first 2-week follow-up. However, while the prednisolone dose was tapered down to 10 mg daily, the disease flared up again. He presented at our hospital with multiple tense bullae and erosions on erythematous pruritic wheals over the neck, trunk, and limbs without mucosal involvement [Figure 1]. Laboratory tests revealed eosinophilia and elevated levels of immunoglobulin E (IgE). There were no positive findings for potential infectious risk factors such as hepatitis B virus, hepatitis C virus, and Cytomegalovirus, as well as tumor markers. The score of Bullous Pemphigoid Disease Area Index (BPDAI) is 69 and the Visual Analog Scale (VAS) of pruritus is 9.Figure 1: Multiple tense bullae and erosions on erythematous pruritic wheals over the (a) neck, anterior chest, and (b) bilateral thighs.Initially, we treated the patient with intravenous methylprednisolone 4 mg/day, doxycycline 100 mg twice daily, systemic antihistamines, and topical steroids. However, we observed hyperglycemia, with poor-controlled blood sugar levels increasing up to 480 mg/dL. After discussing the options with the patient, we prescribed oral baricitinib 4 mg/day. Subsequently, we initiated the tapering of the systemic steroid in 2 days. At 1-week follow-up, the erythema on the body has disappeared and no new blisters have formed. The pruritus has also subsided, leaving only the wounds from the ruptured blisters [Figure 2]. No flare-up was noted after 8-week follow-up without any adverse event, and the BPDAI and VAS of pruritus have decreased to 0 points.Figure 2: (a and b) After 2 weeks of baricitinib treatment, the lesions showed resolution with residual erythema and scarring.Baricitinib is a first-generation Janus kinase (JAK) inhibitor. It works by targeting JAK1 and JAK2 proteins, which play a key role in regulating the immune response and inflammatory pathways.[1] To date, baricitinib has been found to be effective in treating rheumatoid arthritis, alopecia areata, and atopic dermatitis. Although the mechanism of JAK inhibitors in treating blood pressure (BP) is not yet established, several studies have shown its efficacy. Xiao et al. reported successful treatment of concurrent BP and plaque psoriasis with baricitinib in an 83-year-old man, who showed significant improvement and complete remission without adverse effects.[2] Fan and Wang have reported that seven cases of recalcitrant BP were successfully treated with tofacitinib and maintained complete remission during 9 months of follow-up.[3] In the pathogenesis of
{"title":"Successful treatment of bullous pemphigoid with baricitinib: A case report","authors":"Yi-Hsien Chen, Jun Ma, Chien-Ping Chiang, Wei-Ming Wang, Chih-Tsung Hung","doi":"10.4103/ds.ds-d-23-00101","DOIUrl":"https://doi.org/10.4103/ds.ds-d-23-00101","url":null,"abstract":"Dear Editor, A 64-year-old Taiwanese male, nonsmoker, with a history of hypertension and type 2 diabetes mellitus has been regularly taking metformin for glycemic control. The patient was previously diagnosed with biopsy-proven bullous pemphigoid after experiencing multiple itchy erythema and blisters all over the whole body for 3 months. He was treated with prednisolone 10 mg three times daily and azathioprine 25 mg daily. Lesions showed improvement during the first 2-week follow-up. However, while the prednisolone dose was tapered down to 10 mg daily, the disease flared up again. He presented at our hospital with multiple tense bullae and erosions on erythematous pruritic wheals over the neck, trunk, and limbs without mucosal involvement [Figure 1]. Laboratory tests revealed eosinophilia and elevated levels of immunoglobulin E (IgE). There were no positive findings for potential infectious risk factors such as hepatitis B virus, hepatitis C virus, and Cytomegalovirus, as well as tumor markers. The score of Bullous Pemphigoid Disease Area Index (BPDAI) is 69 and the Visual Analog Scale (VAS) of pruritus is 9.Figure 1: Multiple tense bullae and erosions on erythematous pruritic wheals over the (a) neck, anterior chest, and (b) bilateral thighs.Initially, we treated the patient with intravenous methylprednisolone 4 mg/day, doxycycline 100 mg twice daily, systemic antihistamines, and topical steroids. However, we observed hyperglycemia, with poor-controlled blood sugar levels increasing up to 480 mg/dL. After discussing the options with the patient, we prescribed oral baricitinib 4 mg/day. Subsequently, we initiated the tapering of the systemic steroid in 2 days. At 1-week follow-up, the erythema on the body has disappeared and no new blisters have formed. The pruritus has also subsided, leaving only the wounds from the ruptured blisters [Figure 2]. No flare-up was noted after 8-week follow-up without any adverse event, and the BPDAI and VAS of pruritus have decreased to 0 points.Figure 2: (a and b) After 2 weeks of baricitinib treatment, the lesions showed resolution with residual erythema and scarring.Baricitinib is a first-generation Janus kinase (JAK) inhibitor. It works by targeting JAK1 and JAK2 proteins, which play a key role in regulating the immune response and inflammatory pathways.[1] To date, baricitinib has been found to be effective in treating rheumatoid arthritis, alopecia areata, and atopic dermatitis. Although the mechanism of JAK inhibitors in treating blood pressure (BP) is not yet established, several studies have shown its efficacy. Xiao et al. reported successful treatment of concurrent BP and plaque psoriasis with baricitinib in an 83-year-old man, who showed significant improvement and complete remission without adverse effects.[2] Fan and Wang have reported that seven cases of recalcitrant BP were successfully treated with tofacitinib and maintained complete remission during 9 months of follow-up.[3] In the pathogenesis of","PeriodicalId":11107,"journal":{"name":"Dermatologica Sinica","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135913338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.4103/ds.ds-d-23-00100
Ching-Chi Chi, Jin-Ling Ku, Min-Hao Sun, Yi-Chang Yen
Wearing facial masks is a commonly used personal protection measure during the COVID-19 pandemic. However, prolonged use of masks has caused adverse skin reactions in both health-care workers (HCWs) and the public. In this study, we conducted a narrative review of mask-related adverse skin reactions and risk factors. Common mask-related adverse skin reactions include retroauricular dermatitis, cheilitis, rosacea, acne vulgaris, nasal bridge damage, itch, allergic contact dermatitis, and irritant contact dermatitis. Urticaria, facial pigmentation, and maceration were also reported as mask-related adverse skin reactions while the association was rarely reported. Long duration of wearing masks, preexisting skin diseases, and being HCWs are highlighted as definite risk factors. Skin conditions for example oily, dry, and sensitive skin lead to an increased risk of mask-related adverse skin reactions. In conclusion, this review provides a summary of mask-related dermatoses and their prevalence and risk factors. This article can inform the HCWs and the public to better identify mask-related adverse skin reactions and risk factors. Thus, they may adopt appropriate preventative measures based on their individualized circumstances.
{"title":"Mask-related adverse skin reactions and risk factors: A literature review","authors":"Ching-Chi Chi, Jin-Ling Ku, Min-Hao Sun, Yi-Chang Yen","doi":"10.4103/ds.ds-d-23-00100","DOIUrl":"https://doi.org/10.4103/ds.ds-d-23-00100","url":null,"abstract":"Wearing facial masks is a commonly used personal protection measure during the COVID-19 pandemic. However, prolonged use of masks has caused adverse skin reactions in both health-care workers (HCWs) and the public. In this study, we conducted a narrative review of mask-related adverse skin reactions and risk factors. Common mask-related adverse skin reactions include retroauricular dermatitis, cheilitis, rosacea, acne vulgaris, nasal bridge damage, itch, allergic contact dermatitis, and irritant contact dermatitis. Urticaria, facial pigmentation, and maceration were also reported as mask-related adverse skin reactions while the association was rarely reported. Long duration of wearing masks, preexisting skin diseases, and being HCWs are highlighted as definite risk factors. Skin conditions for example oily, dry, and sensitive skin lead to an increased risk of mask-related adverse skin reactions. In conclusion, this review provides a summary of mask-related dermatoses and their prevalence and risk factors. This article can inform the HCWs and the public to better identify mask-related adverse skin reactions and risk factors. Thus, they may adopt appropriate preventative measures based on their individualized circumstances.","PeriodicalId":11107,"journal":{"name":"Dermatologica Sinica","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135913346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Acrocyanosis and retiform purpura as the first manifestation of catastrophic antiphospholipid syndrome in a child: A case report","authors":"CHIH-KAI Wong, Li-Ching Fang, Wei Hung, Yu-Hung Wu","doi":"10.4103/ds.ds-d-22-00086","DOIUrl":"https://doi.org/10.4103/ds.ds-d-22-00086","url":null,"abstract":"","PeriodicalId":11107,"journal":{"name":"Dermatologica Sinica","volume":"24 1","pages":"54 - 55"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87213796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.4103/ds.ds-d-23-00093
Yoshio Kawakami, Toshiyuki Yamamoto
1Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 2Department of Dermatology, Fukushima Medical University, Fukushima, Japan Address for correspondence: Dr. Yoshio Kawakami, Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama 700-8558, Japan. E-mail: [email protected] Received May 15, 2023 Received in revised form July 17, 2023 Accepted August 07, 2023
{"title":"Coexistence of scleredema adultorum of Buschke and psoriatic arthritis: A case report","authors":"Yoshio Kawakami, Toshiyuki Yamamoto","doi":"10.4103/ds.ds-d-23-00093","DOIUrl":"https://doi.org/10.4103/ds.ds-d-23-00093","url":null,"abstract":"1Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 2Department of Dermatology, Fukushima Medical University, Fukushima, Japan Address for correspondence: Dr. Yoshio Kawakami, Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama 700-8558, Japan. E-mail: [email protected] Received May 15, 2023 Received in revised form July 17, 2023 Accepted August 07, 2023","PeriodicalId":11107,"journal":{"name":"Dermatologica Sinica","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135952812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：